Advertisement
Advertisement
AGIO
Agios Pharmaceuticals, Inc.
28.16
USDSponsored
+0.16
+0.57%
May 01, 16:00 UTC -4
Closed
After-Market
27.96
-0.20
-0.72%
AGIO Earnings Reports
Positive Surprise Ratio
AGIO beat 28 of 41 last estimates.
68%
Next Report
Date of Next Report
Jul 29, 2026
Estimate for Q2 26 (Revenue/ EPS)
$19.62M
/-$1.74
Implied change from Q1 26 (Revenue/ EPS)
-5.45%
/+2.96%
Implied change from Q2 25 (Revenue/ EPS)
+57.52%
/-9.84%
Agios Pharmaceuticals, Inc. earnings per share and revenue
On Apr 29, 2026, AGIO reported earnings of -1.69 USD per share (EPS) for Q1 26, beating the estimate of -1.83 USD, resulting in a 7.99% surprise. Revenue reached 20.75 million, compared to an expected 13.92 million, with a 49.08% difference. The market reacted with a +13.10% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -1.74 USD, with revenue projected to reach 19.62 million USD, implying an increase of 2.96% EPS, and decrease of -5.45% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
NovoCure Limited Ordinary Shares
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.52
Actual
-$0.62
Surprise
-18.52%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.32
Actual
-$0.18
Surprise
+45.22%
Pacira BioSciences, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.57
Actual
$0.60
Surprise
+4.42%
Emergent Biosolutions, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.25
Actual
$0.21
Surprise
+183.17%
Amgen Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$4.85
Actual
$5.15
Surprise
+6.15%
Bristol-Myers Squibb Co.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.42
Actual
$1.58
Surprise
+10.95%
Alnylam Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.95
Actual
$1.99
Surprise
+108.95%
Moderna, Inc. Common Stock
Report Date
May 01, 2026 For Q1 26
Estimate
-$3.32
Actual
-$1.18
Surprise
+64.48%
Illumina Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.07
Actual
$1.14
Surprise
+6.94%
Bio-Rad Laboratories, Inc. Class B
Report Date
Apr 30, 2026 For Q1 26
Estimate
$2.00
Actual
$1.89
Surprise
-5.68%
FAQ
What were Agios Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Agios Pharmaceuticals, Inc. reported EPS of -$1.69, beating estimates by 7.99%, and revenue of $20.75M, 49.08% above expectations.
How did the market react to Agios Pharmaceuticals, Inc.'s Q1 2026 earnings?
The stock price moved up 13.1%, changed from $24.80 before the earnings release to $28.05 the day after.
When is Agios Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Jul 29, 2026.
What are the forecasts for Agios Pharmaceuticals, Inc.'s next earnings report?
Based on 7
analysts, Agios Pharmaceuticals, Inc. is expected to report EPS of -$1.74 and revenue of $19.62M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement